Bioelectronics Corp (OTCMKTS:BIEL)
Bioelectronics Corp (OTCMKTS:BIEL) has announced an initial purchase order from Tesco for BioElectronics’ ActiPatch® Musculoskeletal Pain Therapy devices. BioElectronics Corporation Vice President in charge of Sales said the company will be working to collaborate more with the retailer so as to expand its market share in the UK market. BioElectronics Corporation specializes in the production of highly innovated and advanced drug-free and pain management medical solutions.
Bioelectronics Corp (OTCMKTS:BIEL) recently secured a US FDA over-the-counter market approval, a move that has received growing interest from distributers in the international market. The company appointed Multiple Health Pharma Ltd to add to its ActiPatch distributors. Multiple Health Pharma Ltd is a distributor of medical products in Bangladesh. Bioelectronics Corp is seeking to expand its market reach and take advantage of the 1.7 billion populations in the Indian subcontinent. According to Multiple Health Pharma Ltd Managing Director Shah Alam, ActiPatch products offer a better alternative to oral medications.
Bioelectronics Corp (OTCMKTS:BIEL)’s President, Andrew J. Whelan, recently announced the clearance of ActiPatch for over-the-counter sales in a letter that also detailed several accomplishments that the company has made in the recent past as well as laying out the company’s programs in the near future.
He said as a way of expanding the company’s market and supply chain, the company is seeking to partner with “a major OTC marketing partner” who has well established roots in addition to having proven financial and managerial resources to execute a global market penetration.
Whelan added that Bioelectronics Corp (OTCMKTS:BIEL) is working to secure clearance for reimbursement from UK’s and Canada’s National Health System. This is after the company received a request for information on cost benefits of ActiPatch from the Uk’s National Health Service.
Bioelectronics Corp (OTCMKTS:BIEL) is working on completing development and testing of their extra-strength prescription of post-operative, severe-wound care equipment. The company is also at advanced stages of a clinical trial evaluating back pain which is being conducted at Oxford University Hospital. The company’s research and development team is involved in investigating of the efficacy of ActiPatch as a solution to migraine attacks and reducing pain during an attack.
Bioelectronics Corp (OTCMKTS:BIEL) closed the day at $0.0008 exchanging 90.08 Million shares in yesterday’s trading session.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
About the author: Mario grew up in Phoenix, AZ and attended college on a fencing scholarship. After college he went to work for a nationally recognized investment analysis website located in Chicago. For extra money, Mario writes, using a pseudonym, about nano-cap companies with high-growth potentials.